Application of an adapted PRECIS-2 instrument to assess efficacy- and effectiveness-study designs in a systematic review of intervention studies of the hepatitis C virus-care continuum among people who use drugs

References

• Carey T, Yon A, Beadles C, Wines R. Prioritizing future research through examination of research gaps in systematic reviews. 2012. Available from: https://www.pcori.org/assets/Prioritizing-Future-Research-through-Examination-of-Research-Gaps-in-Systematic-Reviews1.pdf. Accessed February 3, 2018.
   Google Scholar
• Miake-Lye IM, Hempel S, Shanman R, Shekelle PG. What is an evidence map? A systematic review of published evidence maps and their definitions, methods, and products. Syst Rev. 2016;5:28.
   PubMed Web of Science ®Google Scholar
• Chalmers I, Fox DM. Increasing the incidence and influence of systematic reviews on health policy and practice. Am J Public Health. 2016;106(1):11–13.
   Web of Science ®Google Scholar
• Singal AG, Higgins PD, Waljee AK. A primer on effectiveness and efficacy trials. Clin Transl Gastroenterol. 2014;5:e45.
   PubMed Web of Science ®Google Scholar
• Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(1):36–44.
   PubMed Web of Science ®Google Scholar
• Umscheid CA. A primer on performing systematic reviews and meta-analyses. Clin Infect Dis. 2013;57(5):725–734.
   Web of Science ®Google Scholar
• Wells KB. Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research. Am J Psychiatry. 1999;156(1):5–10.
   PubMed Web of Science ®Google Scholar
• Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: designing trials that are fit for purpose. BMJ. 2015;350:h2147.
   PubMed Web of Science ®Google Scholar
• Althuis MD, Weed DL, Frankenfeld CL. Evidence-based mapping of design heterogeneity prior to meta-analysis: a systematic review and evidence synthesis. Syst Rev. 2014;3:80.
   Google Scholar
• Karanicolas PJ, Montori VM, Devereaux PJ, Schunemann H, Guyatt GH. A new “mechanistic-practical” framework for designing and interpreting randomized trials. J Clin Epidemiol. 2009;62(5):479–484.
   Web of Science ®Google Scholar
• Solomon SS, Mehta SH, Srikrishnan AK, et al. Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study. Lancet Infect Dis. 2015;15(1):36–45.
   PubMed Web of Science ®Google Scholar
• Smith DJ, Combellick J, Jordan AE, Hagan H. Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): a systematic review and meta-analysis. Int J Drug Policy. 2015;26(10):911–921.
   Web of Science ®Google Scholar
• Ford N, Wiktor S, Kaplan K, et al. Ten priorities for expanding access to HCV treatment for people who inject drugs in low- and middle-income countries. Int J Drug Policy. 2015;26(11):1088–1093.
   PubMed Web of Science ®Google Scholar
• Wolfe D, Luhmann N, Harris M, et al. Human rights and access to hepatitis C treatment for people who inject drugs. Int J Drug Policy. 2015;26(11):1072–1080.
   PubMed Web of Science ®Google Scholar
• Hagan H, Latka MH, Campbell JV, et al. Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities. Clin Infect Dis. 2006;42(5):669–672.
   Web of Science ®Google Scholar
• Corson S, Greenhalgh D, Palmateer N, Weir A, Hutchinson S. Risk of Hepatitis C virus re-infection following spontaneous viral clearance in injecting drug users: a systematic review. Int J Drug Policy. 2011;22(2):102–108.
   Web of Science ®Google Scholar
• Perlman DC, des Jarlais DC, Feelemyer J. Can HIV and hepatitis C virus infection be eliminated among persons who inject drugs? J Addict Dis. 2015;34(2–3):198–205.
   PubMed Web of Science ®Google Scholar
• Trooskin SB, Reynolds H, Kostman JR. Access to costly new hepatitis c drugs: medicine, money, and advocacy. Clin Infect Dis. 2015;61(12):1825–1830.
   PubMed Web of Science ®Google Scholar
• Turner K, Hutchinson S, Vickerman P, et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction. 2011;106(11):1978–1988.
   PubMed Web of Science ®Google Scholar
• Hagan H, Pouget ER, des Jarlais DC. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis. 2011;204(1):74–83.
   PubMed Web of Science ®Google Scholar
• Martin NK, Vickerman P, Miners A, et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology. 2012;55(1):49–57.
   PubMed Web of Science ®Google Scholar
• Martin NK, Vickerman P, Grebely J, et al. Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology. 2013;58(5):1598–1609.
   PubMed Web of Science ®Google Scholar
• Hagan H, Pouget R, des Jarlais DC. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis. 2011 1;204(1):74–83.
   Google Scholar
• van Handel MM, Rose CE, Hallisey EJ, et al. County-level vulnerability assessment for rapid dissemination of HIV or HCV infections among persons who inject drugs, United States. J Acquir Immune Defic Syndr. 2016;73(3):323–331.
   PubMed Web of Science ®Google Scholar
• Perlman DC, Jordan AE, Nash D. Conceptualizing care continua: lessons from HIV, hepatitis C Virus, tuberculosis and implications for the development of improved care and prevention continua. Front Public Health. 2017;4:296.
   Web of Science ®Google Scholar
• Linas BP, Barter DM, Leff JA, et al. The hepatitis C cascade of care: identifying priorities to improve clinical outcomes. PLoS One. 2014;9(5):e97317.
   PubMed Web of Science ®Google Scholar
• Yu ML, Yeh ML, Tsai PC, et al. Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in Taiwan. Medicine (Baltimore). 2015;94(13):e690.
   PubMed Web of Science ®Google Scholar
• Haley SJ, Kreek MJ. A window of opportunity: maximizing the effectiveness of new HCV regimens in the United States with the expansion of the Affordable Care Act. Am J Public Health. 2015;105(3):457–463.
   PubMed Web of Science ®Google Scholar
• Kramer JR, Kanwal F, Richardson P, Mei M, El-Serag HB. Gaps in the achievement of effectiveness of HCV treatment in national VA practice. J Hepatol. 2012;56(2):320–325.
   Web of Science ®Google Scholar
• Kaner E, Beyer F, Dickinson H, et al. Effectiveness of brief alcohol interventions in primary care populations. Cochrane Database Syst Rev. 2007;(2):CD004148.
   Web of Science ®Google Scholar
• Reed JR, Jordan AE, Perlman DC, Smith DJ, Hagan H. The HCV care continuum among people who use drugs: protocol for a systematic review and meta-analysis. Syst Rev. 2016;5(1):110.
   Google Scholar
• Krieger N. Who and what is a “population”? Historical debates, current controversies, and implications for understanding “population health” and rectifying health inequities. Milbank Q. 2012;90(4):634–681.
   PubMed Web of Science ®Google Scholar
• Mangal JP, Rimland D, Marconi VC. The continuum of HIV care in a Veterans’ Affairs clinic. AIDS Res Hum Retroviruses. 2014;30(5):409–415.
   Web of Science ®Google Scholar
• Ali MK, Bullard KM, Gregg EW, Del Rio C. A cascade of care for diabetes in the United States: visualizing the gaps. Ann Iintern Med. 2014;161(10):681–689.
   Web of Science ®Google Scholar
• Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.
   PubMed Web of Science ®Google Scholar
• Johnson KE, Neta G, Dember LM, et al. Use of PRECIS ratings in the National Institutes of Health (NIH) Health Care Systems Research Collaboratory. Trials. 2016;17:32.
   Web of Science ®Google Scholar
• Cruvinel E, Richter KP, Stoney C, et al. CHARTing a path to pragmatic tobacco treatment research. Am J Prev Med. 2016;51(4):630–636.
   Web of Science ®Google Scholar
• Glasgow RE, Gaglio B, Bennett G, et al. Applying the PRECIS criteria to describe three effectiveness trials of weight loss in obese patients with comorbid conditions. Health Serv Res. 2012;47(3 Pt 1):1051–1067.
   Web of Science ®Google Scholar
• Loudon K, Zwarenstein M, Sullivan F, et al. The PRECIS-2 tool has good interrater reliability and modest discriminant validity. J Clin Epidemiol. 2017;88:113–121.
   PubMed Web of Science ®Google Scholar
• PRECIS-2 [homepage on the internet]. 2016. Available from: http://precis-2.org. Accessed July 5, 2017.
   Google Scholar
• StataCorp. Stata statistical software: release 15. College Station (TX): StataCorp; 2017.
   Google Scholar
• IBM. SPSS Statistics for Windows [software]. Armonk, NY: IBM; 2013.
   Google Scholar
• D’Souza G, Arafat R, Hwang L, Cunningham C, Shah S, Reynolds K. Cross-sectional survey of the extent and indicators of hepatitis C virus infection in Houston Department of Health and Human Services’ sexually transmitted disease clinics. J Viral Hepat. 2003;10(2):134–140.
   Web of Science ®Google Scholar
• Gunn RA, Lee MA, Callahan DB, Gonzales P, Murray PJ, Margolis HS. Integrating hepatitis, STD, and HIV services into a drug rehabilitation program. Am J Prev Med. 2005;29(1):27–33.
   Web of Science ®Google Scholar
• Harris KA Jr, Arnsten JH, Litwin AH. Successful integration of hepatitis C evaluation and treatment services with methadone maintenance. J Addict Med. 2010;4(1):20–26.
   PubMed Web of Science ®Google Scholar
• Hennessy RR, Weisfuse IB, Schlanger K. Does integrating viral hepatitis services into a public STD clinic attract injection drug users for care? Public Health Rep. 2007;122 Suppl 2:31–35.
   Google Scholar
• Kapadia F, Latka MH, Hagan H, et al. Design and feasibility of a randomized behavioral intervention to reduce distributive injection risk and improve health-care access among hepatitis C virus positive injection drug users: the Study to Reduce Intravenous Exposures (STRIVE). J Urban Health. 2007;84(1):99–115.
   PubMed Web of Science ®Google Scholar
• Kim AY, Nagami EH, Birch CE, Bowen MJ, Lauer GM, McGovern BH. A simple strategy to identify acute hepatitis C virus infection among newly incarcerated injection drug users. Hepatology. 2013;57(3):944–952.
   Web of Science ®Google Scholar
• Lally MA, MacNevin R, Sergie Z, et al. A model to provide comprehensive testing for HIV, viral hepatitis, and sexually transmitted infections at a short-term drug treatment center. AIDS Patient Care STDs. 2005;19(5):298–305.
   Web of Science ®Google Scholar
• Mallette C, Flynn MA, Promrat K. Outcome of screening for hepatitis C virus infection based on risk factors. Am J Gastroenterol. 2008;103(1):131–137.
   Web of Science ®Google Scholar
• Martinez A, Dimova R, Marks K, et al. Integrated internist — addiction medicine — hepatology model for hepatitis C management for individuals on methadone maintenance. J Viral Hepat. 2012;19(1):47–54.
   Web of Science ®Google Scholar
• Masson CL, Delucchi KL, McKnight C, et al. A randomized trial of a hepatitis care coordination model in methadone maintenance treatment. Am J Public Health. 2013;103(10):e81–e88.
   PubMed Web of Science ®Google Scholar
• McGarry KA, Stein MD, Clarke JG, Friedmann PD. Utilization of preventive health services by HIV-seronegative injection drug users. J Addict Dis. 2002;21(2):93–102.
   PubMed Web of Science ®Google Scholar
• McGovern BH, Wurcel A, Kim AY, et al. Acute hepatitis C virus infection in incarcerated injection drug users. Clin Infect Dis. 2006;42(12):1663–1670.
   Web of Science ®Google Scholar
• Merchant RC, Baird JR, Liu T, Taylor LE, Montague BT, Nirenberg TD. Brief intervention to increase emergency department uptake of combined rapid human immunodeficiency virus and hepatitis C screening among a drug misusing population. Acad Emerg Med. 2014;21(7):752–767.
   Web of Science ®Google Scholar
• Merchant RC, DeLong AK, Liu T, Baird JR. Factors influencing uptake of rapid HIV and hepatitis C screening among drug misusing adult emergency department patients: implications for future HIV/HCV screening interventions. AIDS Behav. 2015;19(11):2025–2035.
   Web of Science ®Google Scholar
• Morano J, Zelenev A, Lombard A, Marcus R, Gibson B, Altice F. Strategies for hepatitis C testing and linkage to care for vulnerable populations: point-of-care and standard HCV testing in a mobile medical clinic. J Community Health. 2014;39(5):922–934.
   PubMed Web of Science ®Google Scholar
• White DA, Anderson ES, Pfeil SK, Trivedi TK, Alter HJ. Results of a rapid hepatitis C virus screening and diagnostic testing program in an urban emergency department. Ann Emerg Med. 2016;67(1):119–128.
   PubMed Web of Science ®Google Scholar
• Brady CW, Coffman CJ, Provenzale D. Compliance with referral for hepatitis C evaluation among veterans. J Clin Gastroenterol. 2007;41(10):927–931.
   Web of Science ®Google Scholar
• Fishbein DA, Lo Y, Reinus JF, Gourevitch MN, Klein RS. Factors associated with successful referral for clinical care of drug users with chronic hepatitis C who have or are at risk for HIV infection. J Acquir Immune Defic Syndr. 2004;37(3):1367–1375.
   PubMed Web of Science ®Google Scholar
• Rifai MA, Moles JK, Lehman LP, van der Linden BJ. Hepatitis C screening and treatment outcomes in patients with substance use/dependence disorders. Psychosomatics. 2006;47(2):112–121.
   Web of Science ®Google Scholar
• Adeyemi OM, Jensen D, Attar B, et al. Hepatitis C treatment eligibility in an urban population with and without HIV coinfection. AIDS Patient Care STDS. 2004;18(4):239–245.
   Web of Science ®Google Scholar
• Bonkovsky HL, Tice AD, Yapp RG, et al. Efficacy and safety of PEGinterferon α-2a/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administration. Am J Gastroenterol. 2008;103(11):2757–2765.
   Web of Science ®Google Scholar
• Allen SA, Spaulding AC, Osei AM, Taylor LE, Cabral AM, Rich JD. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med. 2003;138(3):187–190.
   Web of Science ®Google Scholar
• Bruce RD, Eiserman J, Acosta A, Gote C, Lim JK, Altice FL. Developing a modified directly observed therapy intervention for hepatitis C treatment in a methadone maintenance program: implications for program replication. Am J Drug Alcohol Abuse. 2012;38(3):206–212.
   PubMed Web of Science ®Google Scholar
• Butt AA, Yan P, Shaikh OS, Chung RT, Sherman KE. Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES. Liver Int. 2016;36(5):651–658.
   Web of Science ®Google Scholar
• Ho CJ, Preston C, Fredericks K, et al. A unique model for treating chronic hepatitis C in patients with psychiatric disorders, substance abuse, and/or housing instability. J Addict Med. 2013;7(5):320–324.
   Web of Science ®Google Scholar
• Ho SB, Brau N, Cheung R, et al. Integrated care increases treatment and improves outcomes of patients with chronic hepatitis C virus infection and psychiatric illness or substance abuse. Clin Gastroenterol Hepatol. 2015;13(11):2005–2014.e1–e3.
   Web of Science ®Google Scholar
• Lalezari J, Sullivan JG, Varunok P, et al. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. J Hepatol. 2015;63(2):364–369.
   PubMed Web of Science ®Google Scholar
• Litwin AH, Harris KA Jr, Nahvi S, et al. Successful treatment of chronic hepatitis C with PEGylated interferon in combination with ribavirin in a methadone maintenance treatment program. J Subst Abuse Treat. 2009;37(1):32–40.
   Web of Science ®Google Scholar
• Litwin AH, Soloway IJ, Cockerham-Colas L, et al. Successful treatment of chronic hepatitis C with triple therapy in an opioid agonist treatment program. Int J Drug Policy. 2015;26(10):1014–1019.
   Web of Science ®Google Scholar
• Mehta SH, Lucas GM, Mirel LB, et al. Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS. 2006;20(18):2361–2369.
   PubMed Web of Science ®Google Scholar
• Miller L, Fluker SA, Osborn M, Liu X, Strawder A. Improving access to hepatitis C care for urban, underserved patients using a primary care-based hepatitis C clinic. J Natl Med Assoc. 2012;104(5–6):244–250.
   Web of Science ®Google Scholar
• Nelson RE, Hoop R, Korner E, et al. Predicting discontinuation of PEGylated interferon as a result of lack of efficacy in United States veterans with chronic hepatitis C on dual therapy. Ann Pharmacother. 2014;48(7):826–836.
   Web of Science ®Google Scholar
• Stein MR, Soloway IJ, Jefferson KS, Roose RJ, Arnsten JH, Litwin AH. Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program. J Subst Abuse Treat. 2012;43(4):424–432.
   PubMed Web of Science ®Google Scholar
• Sylvestre DL. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend. 2002;67(2):117–123.
   PubMed Web of Science ®Google Scholar
• Sylvestre DL, Litwin AH, Clements BJ, Gourevitch MN. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. J Subst Abuse Treat. 2005;29(3):159–165.
   PubMed Web of Science ®Google Scholar
• Taylor LE, Bowman SE, Chapman S, et al. Treatment for hepatitis C virus genotype 1 infection in HIV-infected individuals on methadone maintenance therapy. Drug Alcohol Depend. 2011;116(1–3):233–237.
   Web of Science ®Google Scholar
• van Thiel DH, Anantharaju A, Creech S. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse. Am J Gastroenterol. 2003;98(10):2281–2288.
   PubMed Web of Science ®Google Scholar
• Woodrell C, Weiss J, Branch A, et al. Primary care-based hepatitis c treatment outcomes with first-generation direct-acting agents. J Addict Med. 2015;9(5):405–410.
   Web of Science ®Google Scholar
• Gartlehner G, Hansen RA, Nissman D, Lohr KN, Carey TS. A simple and valid tool distinguished efficacy from effectiveness studies. J Clin Epidemiol. 2006;59(10):1040–1048.
   PubMed Web of Science ®Google Scholar
• Gartlehner G, Hansen RA, Nissman D, Lohr KN, Carey TS. Criteria for Distinguishing Effectiveness from Efficacy Trials in Systematic Reviews. Rockville (MD): Agency for Healthcare Research and Quality; 2006.
   Google Scholar
• Heather N. The efficacy-effectiveness distinction in trials of alcohol brief intervention. Addict Sci Clin Pract. 2014;9:13.
   PubMedGoogle Scholar
• Jordan AE, Perlman DC, Smith DJ, Reed J, Hagan H. Use of the PRECIS-II instrument to categorize reports along the efficacy-effectiveness spectrum in an hepatitis C virus care continuum systematic review and meta-analysis. J Clin Epidemiol. 2018;93:66–75.
   Web of Science ®Google Scholar
• Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis. 2009;49(4):561–573.
   Web of Science ®Google Scholar
• Edlin BR, Seal KH, Lorvick J, et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med. 2001;345(3):211–215.
   PubMed Web of Science ®Google Scholar